[Skip to Navigation]
Sign In
JAMA Network Insights
February 2018

Management of the Node-Positive Axilla in Breast Cancer in 2017: Selecting the Right Option

Author Affiliations
  • 1Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Associate Editor for Reviews and CME, JAMA Oncology
JAMA Oncol. 2018;4(2):250-251. doi:10.1001/jamaoncol.2017.3625

The variety of options now available for managing the patient with breast cancer and axillary nodal metastases is confusing. For more than 100 years, axillary lymph node dissection (ALND) was the standard approach, but now, sentinel lymph node biopsy (SLNB) alone, SLNB plus nodal radiotherapy, and neoadjuvant chemotherapy are all alternatives supported by evidence. Herein, I review the data informing patient selection for each of these approaches with the goal of minimizing the use of ALND and its associated morbidity.

Add or change institution